Computational Modeling for Circulating Cell-Free DNA in Clinical Oncology
JCO Clinical Cancer Informatics · 2025-03 · (9)
DOI: 10.1200/cci-24-00224 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift JCO Clinical Cancer Informatics, 2025-03. Verfasst von Linh Nguyen Phuong und 2 weiteren Autor:innen. Beteiligte Einrichtung: Computational Pharmacology and Clinical Oncology Department, Centre Inria d'Université Côte d'Azur, Cancer Research Centre of Marseille, Paoli Calmet…. Hauptthemen laut MEDLINE: Neoplasms, Cell-Free Nucleic Acids, Biomarkers, Tumor, Medical Oncology. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 97 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Liquid biopsy, specifically circulating cell-free DNA (cfDNA), has emerged as a powerful tool for cancer early diagnosis, prognosis, and treatment monitoring over a wide range of cancer types. Computational modeling (CM) of cfDNA data is essential to harness its full potential for real-time, noninvasive insights into tumor biology, enhancing clinical decision making. DESIGN This work reviews CM-cfDNA methods applied to clinical oncology, emphasizing both machine learning (ML) techniques and mechanistic approaches. The latter integrate biological principles, enabling a deeper understanding of cfDNA dynamics and its relationship with tumor evolution. RESULTS Key findings highlight the effectiveness of CM-cfDNA approaches in improving diagnostic accuracy, identifying prognostic markers, and predicting therapeutic outcomes. ML models integrating cfDNA concentration, fragmentation patterns, and mutation detection achieve high sensitivity and specificity for early cancer detection. Mechanistic models describe cfDNA kinetics, linking them to tumor growth and response to treatment, for example, immune checkpoint inhibitors. Longitudinal data and advanced statistical constructs further refine these models for quantification of interindividual and intraindividual variability. CONCLUSION CM-cfDNA represents a pivotal advancement in precision oncology. It bridges the gap between extensive cfDNA data and actionable clinical insights, supporting its integration into routine cancer care. Future efforts should focus on standardizing protocols, validating models across populations, and exploring hybrid approaches combining ML with mechanistic modeling to improve biological understanding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Computational Pharmacology and Clinical Oncology Department, Centre Inria d'Université Côte d'Azur, Cancer Research Centre of Marseille, Paoli Calmettes Institute, Inserm UMR1068, CNRS UMR7258, Aix Marseille University…
- Assistance Publique-Hôpitaux de Marseille, Timone Hospital, Aix Marseille University, Marseille, France.
ORCID-Profile: Linh Nguyen Phuong, Sébastien Benzekry
Zitieren
APA
Nguyen Phuong, L., Salas, S., & Benzekry, S. (2025). Computational Modeling for Circulating Cell-Free DNA in Clinical Oncology. JCO Clinical Cancer Informatics. https://doi.org/10.1200/cci-24-00224
Vancouver
Nguyen Phuong L, Salas S, Benzekry S. Computational Modeling for Circulating Cell-Free DNA in Clinical Oncology. JCO Clinical Cancer Informatics. 2025. doi:10.1200/cci-24-00224
BibTeX
@article{NguyenPhuong2025,
author = {Nguyen Phuong, Linh and Salas, Sébastien and Benzekry, Sébastien},
title = {Computational Modeling for Circulating Cell-Free DNA in Clinical Oncology},
journal = {JCO Clinical Cancer Informatics},
year = {2025},
number = {9},
doi = {10.1200/cci-24-00224}
}
EUVIMED